Share Price and Basic Stock Data
Last Updated: January 2, 2026, 5:04 pm
| PEG Ratio | 17.67 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Mankind Pharma Ltd operates in the pharmaceuticals sector and reported a current market price of ₹2,165 with a market capitalization of ₹89,356 Cr. The company’s revenue from operations has shown consistent growth, rising from ₹3,918 Cr in March 2018 to ₹8,127 Cr in March 2023. For the fiscal year ending March 2025, revenue is projected to reach ₹9,498 Cr, indicating a robust growth trajectory. Recent quarterly sales figures reflect this trend, with Q2 FY2025 sales at ₹2,609 Cr, marking a significant increase from ₹2,258 Cr in Q2 FY2022. The sales growth is complemented by a strong operating profit margin (OPM), which stood at 27% for the latest quarter, reflecting effective cost management and operational efficiency. The company has diversified its product offerings, contributing to a steady increase in top-line performance, which is crucial for sustaining long-term growth amidst competitive pressures in the pharmaceutical industry.
Profitability and Efficiency Metrics
Mankind Pharma’s profitability metrics illustrate a sustained ability to generate earnings, with a net profit of ₹1,666 Cr reported. The company’s return on equity (ROE) stood at 13.89%, while the return on capital employed (ROCE) was 15.0%, indicating effective utilization of capital to generate profit. The operating profit margin has consistently remained above 20%, peaking at 31% in December 2024. Additionally, the interest coverage ratio (ICR) of 8.28x demonstrates the company’s strong ability to meet its interest obligations, reflecting financial health. However, the cash conversion cycle (CCC) of 108 days indicates some inefficiencies in working capital management, as the company takes a relatively long time to convert its investments in inventory and receivables back into cash. This aspect could be an area for improvement to enhance liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Mankind Pharma exhibits significant strength, with total assets amounting to ₹24,862 Cr and total liabilities of ₹23,828 Cr. The company reported reserves of ₹15,469 Cr and borrowings of ₹7,248 Cr, resulting in a low long-term debt-to-equity ratio of 0.38, indicating prudent capital management. The price-to-book value ratio (P/BV) stands at 6.98x, which may suggest that the stock is trading at a premium compared to its book value. Key financial ratios such as the current ratio at 1.23x reflect adequate short-term liquidity. However, the inventory turnover ratio of 6.69x, while improving, remains a focal point for enhancing efficiency in inventory management. The overall financial health of Mankind Pharma positions it favorably against peers in the pharmaceuticals sector, which typically exhibit lower leverage and higher operational efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mankind Pharma reveals a strong promoter holding of 72.67%, indicating a significant level of management commitment and confidence in the company’s future. Foreign institutional investors (FIIs) hold 12.83%, while domestic institutional investors (DIIs) account for 11.91%, reflecting a balanced institutional interest. The number of shareholders has increased to 1,70,347, suggesting growing investor confidence in the company’s prospects. However, the public shareholding has declined to 2.57%, which may limit liquidity in the stock. The gradual reduction in promoter holding from 76.50% in June 2023 to the current level could raise questions about future capital raising or share dilution. Nonetheless, the overall distribution indicates a stable investor base, which is crucial for sustaining stock performance and market sentiment.
Outlook, Risks, and Final Insight
Mankind Pharma’s outlook appears positive, given its strong revenue growth, profitability, and solid balance sheet. The company is well-positioned to capitalize on the growing demand for pharmaceutical products, particularly in emerging markets. However, risks remain, including potential regulatory challenges and competition from generic drug manufacturers, which could impact margins and market share. Additionally, the company’s relatively high CCC indicates a need for improved working capital management to enhance liquidity. If Mankind Pharma can address these operational inefficiencies and maintain its growth trajectory, it is likely to strengthen its position in the pharmaceuticals sector. Investors may consider monitoring the company’s strategic initiatives and operational performance closely, as these factors will play a crucial role in determining future success and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 134 Cr. | 106 | 217/84.3 | 29.6 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,739 Cr. | 434 | 479/192 | 98.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.8 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.5 Cr. | 36.5 | 37.0/17.0 | 127 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,253.00 Cr | 1,149.20 | 54.10 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,258 | 1,936 | 1,872 | 2,092 | 2,260 | 2,209 | 2,007 | 2,413 | 2,544 | 2,414 | 2,127 | 2,541 | 2,609 |
| Expenses | 1,735 | 1,563 | 1,491 | 1,594 | 1,662 | 1,636 | 1,482 | 1,837 | 1,781 | 1,668 | 1,650 | 1,868 | 1,916 |
| Operating Profit | 522 | 374 | 381 | 498 | 598 | 573 | 526 | 576 | 763 | 746 | 477 | 673 | 693 |
| OPM % | 23% | 19% | 20% | 24% | 26% | 26% | 26% | 24% | 30% | 31% | 22% | 26% | 27% |
| Other Income | 69 | 32 | 42 | 87 | 84 | 92 | 109 | 125 | 139 | 70 | 219 | 64 | 78 |
| Interest | 8 | 9 | 1 | 2 | 4 | 4 | 4 | 7 | 3 | 200 | 162 | 147 | 147 |
| Depreciation | 66 | 71 | 67 | 69 | 77 | 90 | 87 | 91 | 90 | 91 | 105 | 97 | 99 |
| Profit before tax | 517 | 326 | 355 | 514 | 601 | 571 | 543 | 603 | 810 | 525 | 429 | 494 | 525 |
| Tax % | 19% | 24% | 21% | 20% | 21% | 15% | 14% | 16% | 20% | 22% | 11% | 16% | 13% |
| Net Profit | 420 | 249 | 281 | 409 | 473 | 487 | 468 | 506 | 645 | 412 | 382 | 413 | 459 |
| EPS in Rs | 10.49 | 6.21 | 7.01 | 10.22 | 11.80 | 12.16 | 11.68 | 12.62 | 16.11 | 9.99 | 9.27 | 10.00 | 11.12 |
Last Updated: December 27, 2025, 8:40 pm
Below is a detailed analysis of the quarterly data for Mankind Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2,609.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,541.00 Cr. (Jun 2025) to 2,609.00 Cr., marking an increase of 68.00 Cr..
- For Expenses, as of Sep 2025, the value is 1,916.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,868.00 Cr. (Jun 2025) to 1,916.00 Cr., marking an increase of 48.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 693.00 Cr.. The value appears strong and on an upward trend. It has increased from 673.00 Cr. (Jun 2025) to 693.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Sep 2025, the value is 27.00%. The value appears strong and on an upward trend. It has increased from 26.00% (Jun 2025) to 27.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 78.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Jun 2025) to 78.00 Cr., marking an increase of 14.00 Cr..
- For Interest, as of Sep 2025, the value is 147.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 147.00 Cr..
- For Depreciation, as of Sep 2025, the value is 99.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 97.00 Cr. (Jun 2025) to 99.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 525.00 Cr.. The value appears strong and on an upward trend. It has increased from 494.00 Cr. (Jun 2025) to 525.00 Cr., marking an increase of 31.00 Cr..
- For Tax %, as of Sep 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 16.00% (Jun 2025) to 13.00%, marking a decrease of 3.00%.
- For Net Profit, as of Sep 2025, the value is 459.00 Cr.. The value appears strong and on an upward trend. It has increased from 413.00 Cr. (Jun 2025) to 459.00 Cr., marking an increase of 46.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 11.12. The value appears strong and on an upward trend. It has increased from 10.00 (Jun 2025) to 11.12, marking an increase of 1.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:05 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,918 | 3,829 | 4,794 | 5,530 | 7,486 | 8,127 | 8,629 | 9,498 | 9,691 |
| Expenses | 3,141 | 3,124 | 3,550 | 4,151 | 5,644 | 6,429 | 6,358 | 6,930 | 7,102 |
| Operating Profit | 778 | 705 | 1,244 | 1,379 | 1,842 | 1,698 | 2,272 | 2,567 | 2,589 |
| OPM % | 20% | 18% | 26% | 25% | 25% | 21% | 26% | 27% | 27% |
| Other Income | 209 | 64 | 94 | 148 | 200 | 163 | 369 | 550 | 432 |
| Interest | 18 | 40 | 11 | 8 | 48 | 28 | 17 | 372 | 656 |
| Depreciation | 28 | 38 | 62 | 78 | 123 | 270 | 335 | 378 | 392 |
| Profit before tax | 941 | 691 | 1,265 | 1,440 | 1,871 | 1,563 | 2,289 | 2,367 | 1,972 |
| Tax % | 26% | 26% | 24% | 25% | 26% | 20% | 18% | 18% | |
| Net Profit | 694 | 514 | 958 | 1,084 | 1,389 | 1,248 | 1,876 | 1,945 | 1,666 |
| EPS in Rs | 17.33 | 12.83 | 23.92 | 27.07 | 34.68 | 31.16 | 46.84 | 47.15 | 40.38 |
| Dividend Payout % | 0% | 0% | 32% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -25.94% | 86.38% | 13.15% | 28.14% | -10.15% | 50.32% | 3.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | 112.32% | -73.23% | 14.98% | -38.29% | 60.47% | -46.64% |
Mankind Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 2:40 pm
Balance Sheet
Last Updated: December 4, 2025, 2:30 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 41 | 41 |
| Reserves | 2,957 | 3,025 | 3,611 | 4,694 | 6,500 | 7,744 | 9,663 | 14,599 | 15,469 |
| Borrowings | 360 | 190 | 3 | 101 | 688 | 5 | 24 | 7,254 | 7,248 |
| Other Liabilities | 652 | 596 | 877 | 1,045 | 1,710 | 1,583 | 1,790 | 1,934 | 2,104 |
| Total Liabilities | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 | 24,862 |
| Fixed Assets | 534 | 778 | 945 | 987 | 2,927 | 3,142 | 3,552 | 3,471 | 3,393 |
| CWIP | 322 | 211 | 148 | 166 | 387 | 495 | 209 | 207 | 248 |
| Investments | 1,402 | 1,698 | 1,784 | 2,397 | 2,526 | 3,102 | 4,215 | 16,683 | 17,611 |
| Other Assets | 1,751 | 1,164 | 1,655 | 2,330 | 3,100 | 2,632 | 3,540 | 3,467 | 3,610 |
| Total Assets | 4,009 | 3,851 | 4,531 | 5,880 | 8,939 | 9,371 | 11,516 | 23,828 | 24,862 |
Below is a detailed analysis of the balance sheet data for Mankind Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 41.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 41.00 Cr..
- For Reserves, as of Sep 2025, the value is 15,469.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,599.00 Cr. (Mar 2025) to 15,469.00 Cr., marking an increase of 870.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,248.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 7,254.00 Cr. (Mar 2025) to 7,248.00 Cr., marking a decrease of 6.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2,104.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,934.00 Cr. (Mar 2025) to 2,104.00 Cr., marking an increase of 170.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 24,862.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23,828.00 Cr. (Mar 2025) to 24,862.00 Cr., marking an increase of 1,034.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,393.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,471.00 Cr. (Mar 2025) to 3,393.00 Cr., marking a decrease of 78.00 Cr..
- For CWIP, as of Sep 2025, the value is 248.00 Cr.. The value appears strong and on an upward trend. It has increased from 207.00 Cr. (Mar 2025) to 248.00 Cr., marking an increase of 41.00 Cr..
- For Investments, as of Sep 2025, the value is 17,611.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,683.00 Cr. (Mar 2025) to 17,611.00 Cr., marking an increase of 928.00 Cr..
- For Other Assets, as of Sep 2025, the value is 3,610.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,467.00 Cr. (Mar 2025) to 3,610.00 Cr., marking an increase of 143.00 Cr..
- For Total Assets, as of Sep 2025, the value is 24,862.00 Cr.. The value appears strong and on an upward trend. It has increased from 23,828.00 Cr. (Mar 2025) to 24,862.00 Cr., marking an increase of 1,034.00 Cr..
Notably, the Reserves (15,469.00 Cr.) exceed the Borrowings (7,248.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 418.00 | 515.00 | -2.00 | -100.00 | -687.00 | -4.00 | -22.00 | -5.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 23 | 13 | 32 | 24 | 23 | 22 | 33 | 34 |
| Inventory Days | 120 | 126 | 124 | 169 | 183 | 132 | 160 | 153 |
| Days Payable | 115 | 101 | 113 | 122 | 133 | 103 | 75 | 79 |
| Cash Conversion Cycle | 27 | 38 | 43 | 72 | 73 | 52 | 118 | 108 |
| Working Capital Days | 95 | 44 | 41 | 42 | 26 | 40 | 55 | -48 |
| ROCE % | 22% | 36% | 33% | 30% | 21% | 24% | 15% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large Cap Fund | 4,072,930 | 1.65 | 916.82 | N/A | N/A | N/A |
| HDFC Large Cap Fund | 2,664,492 | 1.48 | 599.78 | 2,571,369 | 2025-12-15 06:13:35 | 3.62% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,444,988 | 5.04 | 325.27 | N/A | N/A | N/A |
| Axis ELSS Tax Saver Fund | 1,330,911 | 0.85 | 299.59 | 1,961,633 | 2025-10-16 16:06:35 | -32.15% |
| SBI Contra Fund | 1,328,039 | 0.6 | 298.94 | N/A | N/A | N/A |
| Aditya Birla Sun Life Flexi Cap Fund | 1,325,544 | 1.2 | 298.38 | 1,310,000 | 2025-12-15 08:42:29 | 1.19% |
| Nippon India Growth Mid Cap Fund | 1,279,034 | 0.68 | 287.91 | N/A | N/A | N/A |
| Nippon India Large Cap Fund | 1,278,370 | 0.57 | 287.76 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 1,076,417 | 1.83 | 242.3 | N/A | N/A | N/A |
| Axis Focused Fund | 1,037,596 | 1.88 | 233.56 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 49.28 | 47.75 | 32.00 | 35.78 | 31.59 |
| Diluted EPS (Rs.) | 49.20 | 47.68 | 32.00 | 35.78 | 31.59 |
| Cash EPS (Rs.) | 63.50 | 58.03 | 40.52 | 40.07 | 34.96 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 347.37 | 239.04 | 190.30 | 157.68 | 121.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 347.37 | 239.04 | 190.30 | 157.68 | 121.39 |
| Revenue From Operations / Share (Rs.) | 295.87 | 257.99 | 218.41 | 194.25 | 155.13 |
| PBDIT / Share (Rs.) | 86.15 | 70.29 | 50.66 | 54.55 | 45.41 |
| PBIT / Share (Rs.) | 71.10 | 60.35 | 42.52 | 50.39 | 42.44 |
| PBT / Share (Rs.) | 60.69 | 59.52 | 41.41 | 48.93 | 41.94 |
| Net Profit / Share (Rs.) | 48.45 | 48.09 | 32.38 | 35.91 | 31.99 |
| NP After MI And SOA / Share (Rs.) | 48.25 | 47.75 | 32.00 | 35.78 | 31.59 |
| PBDIT Margin (%) | 29.11 | 27.24 | 23.19 | 28.08 | 29.27 |
| PBIT Margin (%) | 24.03 | 23.39 | 19.46 | 25.94 | 27.35 |
| PBT Margin (%) | 20.51 | 23.06 | 18.95 | 25.18 | 27.03 |
| Net Profit Margin (%) | 16.37 | 18.64 | 14.82 | 18.48 | 20.61 |
| NP After MI And SOA Margin (%) | 16.30 | 18.50 | 14.65 | 18.42 | 20.36 |
| Return on Networth / Equity (%) | 13.89 | 20.43 | 17.24 | 23.28 | 26.79 |
| Return on Capital Employeed (%) | 13.27 | 24.56 | 21.69 | 30.94 | 33.87 |
| Return On Assets (%) | 7.17 | 15.98 | 13.19 | 15.67 | 19.85 |
| Long Term Debt / Equity (X) | 0.38 | 0.00 | 0.00 | 0.01 | 0.01 |
| Total Debt / Equity (X) | 0.59 | 0.02 | 0.02 | 0.14 | 0.05 |
| Asset Turnover Ratio (%) | 0.61 | 0.95 | 0.87 | 0.98 | 1.01 |
| Current Ratio (X) | 1.23 | 3.10 | 2.32 | 1.68 | 2.89 |
| Quick Ratio (X) | 0.86 | 2.37 | 1.52 | 1.01 | 2.01 |
| Inventory Turnover Ratio (X) | 6.69 | 1.21 | 0.50 | 0.64 | 0.57 |
| Interest Coverage Ratio (X) | 8.28 | 83.98 | 45.63 | 37.29 | 90.29 |
| Interest Coverage Ratio (Post Tax) (X) | 5.64 | 58.45 | 30.17 | 25.54 | 64.60 |
| Enterprise Value (Cr.) | 108143.49 | 91239.85 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 8.86 | 8.83 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 30.42 | 32.40 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 8.19 | 8.90 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 6.98 | 9.83 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 8.19 | 8.90 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Mankind Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 49.28. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 49.28, marking an increase of 1.53.
- For Diluted EPS (Rs.), as of Mar 25, the value is 49.20. This value is within the healthy range. It has increased from 47.68 (Mar 24) to 49.20, marking an increase of 1.52.
- For Cash EPS (Rs.), as of Mar 25, the value is 63.50. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 63.50, marking an increase of 5.47.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 347.37. It has increased from 239.04 (Mar 24) to 347.37, marking an increase of 108.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 295.87. It has increased from 257.99 (Mar 24) to 295.87, marking an increase of 37.88.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 86.15. This value is within the healthy range. It has increased from 70.29 (Mar 24) to 86.15, marking an increase of 15.86.
- For PBIT / Share (Rs.), as of Mar 25, the value is 71.10. This value is within the healthy range. It has increased from 60.35 (Mar 24) to 71.10, marking an increase of 10.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 60.69. This value is within the healthy range. It has increased from 59.52 (Mar 24) to 60.69, marking an increase of 1.17.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 48.45. This value is within the healthy range. It has increased from 48.09 (Mar 24) to 48.45, marking an increase of 0.36.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 48.25. This value is within the healthy range. It has increased from 47.75 (Mar 24) to 48.25, marking an increase of 0.50.
- For PBDIT Margin (%), as of Mar 25, the value is 29.11. This value is within the healthy range. It has increased from 27.24 (Mar 24) to 29.11, marking an increase of 1.87.
- For PBIT Margin (%), as of Mar 25, the value is 24.03. This value exceeds the healthy maximum of 20. It has increased from 23.39 (Mar 24) to 24.03, marking an increase of 0.64.
- For PBT Margin (%), as of Mar 25, the value is 20.51. This value is within the healthy range. It has decreased from 23.06 (Mar 24) to 20.51, marking a decrease of 2.55.
- For Net Profit Margin (%), as of Mar 25, the value is 16.37. This value exceeds the healthy maximum of 10. It has decreased from 18.64 (Mar 24) to 16.37, marking a decrease of 2.27.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has decreased from 18.50 (Mar 24) to 16.30, marking a decrease of 2.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.89. This value is below the healthy minimum of 15. It has decreased from 20.43 (Mar 24) to 13.89, marking a decrease of 6.54.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.27. This value is within the healthy range. It has decreased from 24.56 (Mar 24) to 13.27, marking a decrease of 11.29.
- For Return On Assets (%), as of Mar 25, the value is 7.17. This value is within the healthy range. It has decreased from 15.98 (Mar 24) to 7.17, marking a decrease of 8.81.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.38, marking an increase of 0.38.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.02 (Mar 24) to 0.59, marking an increase of 0.57.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.61. It has decreased from 0.95 (Mar 24) to 0.61, marking a decrease of 0.34.
- For Current Ratio (X), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 1.5. It has decreased from 3.10 (Mar 24) to 1.23, marking a decrease of 1.87.
- For Quick Ratio (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 2.37 (Mar 24) to 0.86, marking a decrease of 1.51.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.69. This value is within the healthy range. It has increased from 1.21 (Mar 24) to 6.69, marking an increase of 5.48.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 8.28. This value is within the healthy range. It has decreased from 83.98 (Mar 24) to 8.28, marking a decrease of 75.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.64. This value is within the healthy range. It has decreased from 58.45 (Mar 24) to 5.64, marking a decrease of 52.81.
- For Enterprise Value (Cr.), as of Mar 25, the value is 108,143.49. It has increased from 91,239.85 (Mar 24) to 108,143.49, marking an increase of 16,903.64.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.86. This value exceeds the healthy maximum of 3. It has increased from 8.83 (Mar 24) to 8.86, marking an increase of 0.03.
- For EV / EBITDA (X), as of Mar 25, the value is 30.42. This value exceeds the healthy maximum of 15. It has decreased from 32.40 (Mar 24) to 30.42, marking a decrease of 1.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
- For Price / BV (X), as of Mar 25, the value is 6.98. This value exceeds the healthy maximum of 3. It has decreased from 9.83 (Mar 24) to 6.98, marking a decrease of 2.85.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.19. This value exceeds the healthy maximum of 3. It has decreased from 8.90 (Mar 24) to 8.19, marking a decrease of 0.71.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mankind Pharma Ltd:
- Net Profit Margin: 16.37%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.27% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.89% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.86
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 54.6 (Industry average Stock P/E: 54.1)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 16.37%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 208, Okhla Industrial Estate, Phase-III, New Delhi Delhi 110020 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Juneja | Chairman & Wholetime Director |
| Mr. Rajeev Juneja | Vice Chairman & Mng.Director |
| Ms. Sheetal Arora | Whole Time Director |
| Mr. Satish Kumar Sharma | Whole Time Director |
| Mr. Vivek Kalra | Independent Director |
| Mr. Tilokchand Punamchand Ostwal | Independent Director |
| Mr. Bharat Anand | Independent Director |
| Ms. Vijaya Sampath | Independent Director |
FAQ
What is the intrinsic value of Mankind Pharma Ltd?
Mankind Pharma Ltd's intrinsic value (as of 02 January 2026) is ₹2284.03 which is 3.68% higher the current market price of ₹2,203.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹90,922 Cr. market cap, FY2025-2026 high/low of ₹2,998/2,090, reserves of ₹15,469 Cr, and liabilities of ₹24,862 Cr.
What is the Market Cap of Mankind Pharma Ltd?
The Market Cap of Mankind Pharma Ltd is 90,922 Cr..
What is the current Stock Price of Mankind Pharma Ltd as on 02 January 2026?
The current stock price of Mankind Pharma Ltd as on 02 January 2026 is ₹2,203.
What is the High / Low of Mankind Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mankind Pharma Ltd stocks is ₹2,998/2,090.
What is the Stock P/E of Mankind Pharma Ltd?
The Stock P/E of Mankind Pharma Ltd is 54.6.
What is the Book Value of Mankind Pharma Ltd?
The Book Value of Mankind Pharma Ltd is 376.
What is the Dividend Yield of Mankind Pharma Ltd?
The Dividend Yield of Mankind Pharma Ltd is 0.05 %.
What is the ROCE of Mankind Pharma Ltd?
The ROCE of Mankind Pharma Ltd is 15.0 %.
What is the ROE of Mankind Pharma Ltd?
The ROE of Mankind Pharma Ltd is 13.9 %.
What is the Face Value of Mankind Pharma Ltd?
The Face Value of Mankind Pharma Ltd is 1.00.